iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Lilly weight-loss drug Zepbound new US surpass Wegovy for first time GLP-1 Antagonists Increase Plan Drug

Glucagon-like peptide-1 (GLP-1) agonist therapies are increasingly being used for type 2 diabetes and obesity, but evidence now shows they also reduce inflammation across multiple organs through mechanisms related and unrelated to weight-loss-driven metabolic improvements

In addition to confirm comparable efficacy to injectables, oral small molecules need to show the beneficial cardiovascular effects seen with semaglutide

A man at the bottom of a normal range can feel terrible and deserve treatment

With the global GLP-1 market projected to grow significantly in the coming years, this move could potentially drive substantial revenue growth for the company

Our experienced providers at Be Medispa perform these treatments daily, providing women with expert care